Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-GEMOX in Refractory/Relapsed Patients With CD 20 Positive Diffuse Large B-cell Lymphoma
NCT00169195Phase 2Completed
- Sponsor
- Lymphoma Study Association
- Start
- Apr 2003
- Primary completion
- Nov 2012
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, oxaliplatin and rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Lymphoma Study Association. Primary endpoint: Overall Response Rate at 8 weeks. Started Apr 2003; status: completed.
02
Drugs
gemcitabineoxaliplatinrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00169195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00169195.